Additional info
Which are the industrially-driven development units at the ICIQ?
CRYSFORMA (Solid State Development - Crystallography - Polymorphism)
Crysforma provides complete scientific support for the discovery, analysis and scale-up of polymorphs, hydrates, amorphous phases, salts and co-crystals of active pharmaceutical ingredients or intermediates.
The main working areas are:
- The modification of the solid state properties of active compounds to obtain the most suitable for the desired application (polymorphism, salts and co-crystal screenings).
- The optimisation of crystallisation processes to improve the development stages and to obtain the solids with the desired properties (purity, particle size, polymorph, morphology,…).
- The characterisation of the solid state of drug substance and drug product (PXRD, SCXRD, microED, DSC, TGA, DVS, PSD, IR, Raman, NMR, synchrotron…).
- Supporting the IP protection of new generated solid forms.
Crysforma has developed its own crystallisation screening methodology based on the combination of several crystallisation techniques and the individual monitoring of the experiments by highly skilled scientists to maximise the information extracted from each crystallisation. Our projects are always carried out in close collaboration with the client, adapted to the customer’s needs and under strict confidentiality conditions.
HIGH THROUGHPUT EXPERIMENTATION LABORATORY (HTE)
The High Throughput Experimentation (HTE) laboratory is a facility that makes accessible to all ICIQ researchers the instrumentation and know-how to run a large number of reactions and analyze them in a short period of time.The facility is set up to run different kinds of reactions in 24 or 96 well plates, including those that are air sensitive, reactions with reactive gases or reactions under pressure conditions. Moreover, the Laboratory is stocked with a large number of reagents, solvents, metals and ligands to run the reactions.
Regarding the analysis of the reactions, the lab is equipped with an NMR spectrometer and three chromatographs, a GC-MS, a UHPLC-MS and a supercritical CO2 chromatograph with diode array or MS detector.To speed up the run processes, the lab is also equipped with specific software to prepare the experiments and analyze the results coming from the chromatographs.This laboratory has received funding from Agencia Estatal de Investigación/Ministerio de Ciencia, Innovación y Universidades (Severo Ochoa Excellence Programme CEX2019-000925-S, MCIN/AEI/10.13039/501100011033).
MEDICINAL CHEMISTRY
The KTT-MedChem Unit is specialised in the development of drug discovery and medicinal chemistry projects in collaboration with pharmaceutical companies and biomedical research institutions. Our expertise spans across early stage hit finding to clinical candidate discovery. The MedChem Unit counts with highly qualified PhD scientific personnel, with extended experience in the development of medicinal chemistry projects, and the ICIQ state-of-art equipment and resources to offer high-quality and optimal solutions for Medicinal Chemistry projects.
We have significant expertise in the optimisation of HTS hits and lead compounds, taking into account principles of IP, lead-likeness, synthetic feasibility and ADME properties. Wherever appropriate, computational chemistry capabilities are used in ligand- and structure-based methods, in order to prioritise new compounds to be synthesised. Parallel synthesis and semiautomated purification systems enable the synthesis of chemical libraries for hit and lead optimisation. Additionally, the possibility of using ICIQ-High Throughput Experimentation (HTE) technology can accelerate the discovery and implementation of new and efficient synthetic methodologies.
